KRTAP19-5: A Potential Drug Target and Biomarker (G337972)

Target Name: KRTAP19-5

NCBI ID: G337972

KRTAP19-5

Other Name(s): KAP19.5 | keratin associated protein 19-5 | KR195_HUMAN | Keratin-associated protein 19-5 | Keratin associated protein 19-5

KRTAP19-5: A Potential Drug Target and Biomarker

KRTAP19-5, also known as KAP19.5, is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It is a member of the KRTAS family, which includes known drug targets such as KRAS and KLF1. KRTAP19-5 has been shown to play a role in several cellular processes, including cell signaling, cell adhesion, and inflammation. As a result, KRTAP19-5 has potential as a drug target and biomarker.

The KRTAS family is known for its role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. KRAS, the most well-known gene in the family, is a primary driver of cancer growth and progression. Similarly, KLF1 has been shown to play a role in the development and progression of neurodegenerative diseases such as Alzheimer's disease.

KRTAP19-5 is expressed in various tissues of the body and has been shown to be involved in several cellular processes. (Image: courtesy of PubMed)

Recent studies have suggested that KRTAP19-5 may have potential as a drug target. For example, researchers have shown that inhibiting KRTAP19-5 can reduce the migration and invasion of cancer cells. Additionally, KRTAP19-5 has been shown to play a role in cell signaling, and inhibition of its activity has been shown to reduce the formation of blood-brain barrier-derived neurotrophic factor (BDNF) in neurodegenerative diseases.

In addition to its potential as a drug target, KRTAP19-5 has also been shown to be a potential biomarker. The KRTAS family has been shown to be involved in several cellular processes that are associated with aging and age-related diseases, including cognitive decline, Alzheimer's disease, and cancer. KRTAP19-5 has been shown to be involved in the formation of amyloid plaques, a hallmark of Alzheimer's disease, and has been shown to be involved in the regulation of neurogenesis.

Given the potential role of KRTAP19-5 in several cellular processes that are associated with aging and age-related diseases, it is a promising candidate as a biomarker for these conditions. Additionally, the KRTAS family is known for its role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, making KRTAP19-5 a potential drug target for these conditions as well.

In conclusion, KRTAP19-5 is a protein that has been shown to play a role in several cellular processes, including cell signaling, cell adhesion, and inflammation. Its potential as a drug target and biomarker make it an attractive candidate for further research. Further studies are needed to fully understand its role in these processes and its potential as a drug and biomarker.

Protein Name: Keratin Associated Protein 19-5

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP19-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP19-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets